HDAC9 and cardiovascular disorder: In a community sample of >330,000 adults, we found confirmatory evidence in support of HDAC9 as a key regulator and potential therapeutic target for VSMC-driven cardiovascular disease, with suggestive evidence of a reverse effect on kidney disease.